Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial Publisher Pubmed

Mahmoudi H¹ ; Rostami A¹ ; Tavakolpour S¹ ; Nili A¹ ; Teimourpour A² ; Salehi Farid A¹ ; Abedini R¹ ; Amini M¹ ; Daneshpazhooh M¹

Source: Journal of Dermatological Treatment Published:2022

Abstract

Background: Frontal fibrosing alopecia (FFA) is a scarring alopecia with no promising treatment. Objective: To evaluate the additive efficacy of oral isotretinoin to topical treatments. Methods: Between November 2017 and August 2018, FFA patients were randomly assigned to receive either isotretinoin (20 mg/d) plus topical treatments (clobetasol 0.05% and tacrolimus 0.1%) or monotherapy with topical treatments. Treatments’ efficacy was evaluated through Frontal Fibrosing Alopecia Severity Index (FFASI) after two and 6 months. Results: From 38 participants, 28 patients completed the study. Facial papules improved after 6 months (p value <.001) in the isotretinoin group. Moreover, frontotemporal hairline (p values for frontal <.001; R lateral: 0.03; L Lateral: 0.02), total scalp margins, total additional features’ scores, and total combined (p value <.001 for all) improved more in the isotretinoin group than in the control group. Frontal band improved in the treatment group (p value:.02). Frontal margin (p value:.01), R lateral (p value:.01), total scalp (p value <.01), and combined total scores (p value:.01) worsened in the control group. Isotretinoin-related side-effects included lip dryness, telogen effluvium, and malaise. Limitations: Small sample size and lost to follow-up. Conclusion: Isotretinoin combined with topical treatments is more effective than monotherapy with clobetasol and tacrolimus for FFA. Clinical Trial Code: (IRCT.ir) IRCT2017091736173N1. © 2020 Taylor & Francis Group, LLC.

Related Docs

View other Related Docs

1. Lichen Planopilaris: Retrospective Study on the Characteristics and Treatment of 291 Patients, Journal of Dermatological Treatment (2019)

2. Evaluating the Combined Efficacy of Oral Isotretinoin and Topical Tacrolimus Versus Oral Finasteride and Topical Tacrolimus in Frontal Fibrosing Alopecia—A Randomized Controlled Trial, Journal of Cosmetic Dermatology (2023)

3. Frontal Fibrosing Alopecia: An Update on the Hypothesis of Pathogenesis and Treatment, International Journal of Women's Dermatology (2019)

Experts (# of related papers)

View all Related Experts

Robabeh Abedini (5)

Maryam Nasimi (5)

Other Related Docs

4. Facial Papules Are Early Sign of Frontal Fibrosing Alopecia: A Cross-Sectional Study, Acta Medica Iranica (2020)

5. Comparison of Systemic Mycophenolate Mofetil With Topical Clobetasol in Lichen Planopilaris: A Parallel-Group, Assessor- and Analyst-Blinded, Randomized Controlled Trial, American Journal of Clinical Dermatology (2015)

6. Assessment of Health-Related Quality of Life in Patients With Frontal Fibrosing Alopecia, Journal of Cosmetic Dermatology (2022)

7. Lichen Planopilaris: Histopathological Survey of 70 Vertical Sections of Scalp Biopsies, Iranian Journal of Dermatology (2022)

8. Jak Inhibitors in the Treatment of Lichen Planopilaris, Skin Appendage Disorders (2024)

9. The Efficacy and Safety of Oral Low Dose Naltrexone Versus Placebo in the Patients With Lichen Planopilaris: A Randomized Controlled Clinical Trial, Journal of Dermatological Treatment (2022)

10. Efficacy, Safety, Tolerability, and Satisfaction of N-Acetylcysteine and Pentoxifylline in Lichen Planopilaris Patients Under Treatment With Topical Clobetasol: A Triple Arm Blinded Randomized Controlled Trial, Dermatologic Therapy (2022)

11. Comparison of the Effects of 665 Nm Low Level Diode Laser Hat Versus and a Combination of 665 Nm and 808Nm Low Level Diode Laser Scanner of Hair Growth in Androgenic Alopecia, Journal of Cosmetic and Laser Therapy (2017)

12. A Randomized Trial of Diphenylcyclopropenone (Dpcp) Combined With Anthralin Versus Dpcp Alone for Treating Moderate to Severe Alopecia Areata, International Immunopharmacology (2021)

13. A Prospective Comparative Study of Two Regimens of Diphenylcyclopropenone (Dpcp) in the Treatment of Alopecia Areata, International Immunopharmacology (2021)

14. Efficacy and Safety of Tofacitinib for Treatment of Alopecia Areata in Children: A Systematic Review and Meta-Analysis, Journal of Cosmetic Dermatology (2022)

15. The Efficacy of the Combination of Topical Minoxidil and Oral Spironolactone Compared With the Combination of Topical Minoxidil and Oral Finasteride in Women With Androgenic Alopecia, Female and Male Hair Loss Patterns: A Blinded Randomized Clinical Trial, Journal of Cosmetic Dermatology (2024)

16. Autologous Adipose Tissue Injection in the Treatment of Alopecia: A Mini-Review, Journal of Cosmetic Dermatology (2024)

17. Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children, Dermatologic Therapy (2024)

18. Evaluation of Serum Level of Sex Hormones in Women With Frontal Fibrosing Alopecia in Comparison to Healthy Controls, Dermatologic Therapy (2020)

19. Effective Combination Therapy With High Concentration of Minoxidil and Carboxygas in Resistant Androgenetic Alopecia: Report of Nine Cases, Journal of Cosmetic Dermatology (2020)

20. Distinguishing Immunohistochemical Features of Alopecia Areata From Androgenic Alopecia, Journal of Cosmetic Dermatology (2019)

Style	Citing Format
MLA	Mahmoudi H, et al.. "Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial." Journal of Dermatological Treatment, vol. 33, no. 1, 2022, pp. 284-290.
APA	Mahmoudi H, Rostami A, Tavakolpour S, Nili A, Teimourpour A, Salehi Farid A, Abedini R, Amini M, Daneshpazhooh M (2022). Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial. Journal of Dermatological Treatment, 33(1), 284-290.
Chicago	Mahmoudi H, Rostami A, Tavakolpour S, Nili A, Teimourpour A, Salehi Farid A, Abedini R, Amini M, Daneshpazhooh M. "Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial." Journal of Dermatological Treatment 33, no. 1 (2022): 284-290.
Harvard	Mahmoudi H et al. (2022) 'Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial', Journal of Dermatological Treatment, 33(1), pp. 284-290.
Vancouver	Mahmoudi H, Rostami A, Tavakolpour S, Nili A, Teimourpour A, Salehi Farid A, et al.. Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial. Journal of Dermatological Treatment. 2022;33(1):284-290.
BibTex	@article{ author = {Mahmoudi H and Rostami A and Tavakolpour S and Nili A and Teimourpour A and Salehi Farid A and Abedini R and Amini M and Daneshpazhooh M}, title = {Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial}, journal = {Journal of Dermatological Treatment}, volume = {33}, number = {1}, pages = {284-290}, year = {2022} }
RIS	TY - JOUR AU - Mahmoudi H AU - Rostami A AU - Tavakolpour S AU - Nili A AU - Teimourpour A AU - Salehi Farid A AU - Abedini R AU - Amini M AU - Daneshpazhooh M TI - Oral Isotretinoin Combined With Topical Clobetasol 0.05% and Tacrolimus 0.1% for the Treatment of Frontal Fibrosing Alopecia: A Randomized Controlled Trial JO - Journal of Dermatological Treatment VL - 33 IS - 1 SP - 284 EP - 290 PY - 2022 ER -

Science Communicator Platform

Authors

Abstract